Raras
Buscar doenças, sintomas, genes...
Oligodendroglioma anaplásico
ORPHA:251630CID-10 · C71.9CID-11 · 2A00.0YDOENÇA RARA

Oligodendroglioma grau III da OMS com características morfológicas malignas focais ou difusas (pleomorfismo nuclear proeminente, mitoses e celularidade aumentada).

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Oligodendroglioma grau III da OMS com características morfológicas malignas focais ou difusas (pleomorfismo nuclear proeminente, mitoses e celularidade aumentada).

Pesquisas ativas
12 ensaios
244 total registrados no ClinicalTrials.gov
Publicações científicas
661 artigos
Último publicado: 2026 Mar 18

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
<1 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.09
Europe
Início
Adult
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: C71.9
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico661PubMed
Últimos 10 anos200publicações
Pico201932 papers
Linha do tempo
2026Hoje · 2026🧪 1991Primeiro ensaio clínico📈 2019Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

2 genes identificados com associação a esta condição. Padrão de herança: Not applicable.

IDH2Isocitrate dehydrogenase [NADP], mitochondrialBiomarker tested inAltamente restrito
FUNÇÃO

Plays a role in intermediary metabolism and energy production (PubMed:19228619, PubMed:22416140). It may tightly associate or interact with the pyruvate dehydrogenase complex (PubMed:19228619, PubMed:22416140)

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (4)
Citric acid cycle (TCA cycle)Maturation of TCA enzymes and regulation of TCA cycleMitochondrial protein degradationTranscriptional activation of mitochondrial biogenesis
MECANISMO DE DOENÇA

D-2-hydroxyglutaric aciduria 2

A neurometabolic disorder causing developmental delay, epilepsy, hypotonia, and dysmorphic features. Both a mild and a severe phenotype exist. The severe phenotype is homogeneous and is characterized by early infantile-onset epileptic encephalopathy and cardiomyopathy. The mild phenotype has a more variable clinical presentation. Diagnosis is based on the presence of an excess of D-2-hydroxyglutaric acid in the urine.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
442.8 TPM
Coração - Ventrículo esquerdo
311.5 TPM
Rim - Medula
273.8 TPM
Linfócitos
186.0 TPM
Fígado
184.7 TPM
OUTRAS DOENÇAS (13)
d-2-hydroxyglutaric aciduria 2anaplastic oligodendrogliomagemistocytic astrocytomaoligoastrocytoma
HGNC:5383UniProt:P48735
POT1Protection of telomeres protein 1Major susceptibility factor inTolerante
FUNÇÃO

Component of the telomerase ribonucleoprotein (RNP) complex that is essential for the replication of chromosome termini. Is a component of the double-stranded telomeric DNA-binding TRF1 complex which is involved in the regulation of telomere length by cis-inhibition of telomerase. Also acts as a single-stranded telomeric DNA-binding protein and thus may act as a downstream effector of the TRF1 complex and may transduce information about telomere maintenance and/or length to the telomere terminus

LOCALIZAÇÃO

NucleusChromosome, telomere

VIAS BIOLÓGICAS (10)
DNA Damage/Telomere Stress Induced SenescencePackaging Of Telomere EndsMeiotic synapsisInhibition of DNA recombination at telomereTelomere C-strand (Lagging Strand) Synthesis
MECANISMO DE DOENÇA

Tumor predisposition syndrome 3

An autosomal dominant disorder characterized by an increased risk for the development of various types of benign and malignant neoplasms throughout life, with age-dependent penetrance. Affected individuals can develop neoplasms involving epithelial, mesenchymal, and neuronal tissues, as well as lymphoid and myeloid cancers. The disorder is associated with elongated telomeres.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
22.7 TPM
Nervo tibial
15.9 TPM
Testículo
15.3 TPM
Cervix Ectocervix
13.7 TPM
Útero
13.5 TPM
OUTRAS DOENÇAS (7)
tumor predisposition syndrome 3pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 8cerebroretinal microangiopathy with calcifications and cysts 3oligodendroglioma
HGNC:17284UniProt:Q9NUX5

Variantes genéticas (ClinVar)

550 variantes patogênicas registradas no ClinVar.

🧬 POT1: NM_015450.3(POT1):c.1686+1G>C ()
🧬 POT1: NM_015450.3(POT1):c.172dup (p.Thr58fs) ()
🧬 POT1: NM_015450.3(POT1):c.1353T>A (p.Cys451Ter) ()
🧬 POT1: NM_015450.3(POT1):c.198_217delinsAGGGCTTC (p.Tyr66_Tyr73delinsTer) ()
🧬 POT1: NM_015450.3(POT1):c.878_879insT (p.Glu293fs) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 1 variantes classificadas pelo ClinVar.

1
Patogênica (100.0%)
VARIANTES MAIS SIGNIFICATIVAS
CIC: NM_001386298.1(CIC):c.3370C>T (p.Arg1124Trp) [Likely pathogenic]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado1
2Fase 24
1Fase 112
·Pré-clínico3
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Oligodendroglioma anaplásico

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

5 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

244 ensaios clínicos encontrados, 12 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
247 papers (10 anos)
#1

Anesthesia management in a pregnant woman with a giant temporoparietal anaplastic oligodendroglioma: a case report.

Journal of medical case reports2026 Mar 18

Brain tumors during pregnancy are rare and pose unique challenges in diagnosis, management, and anesthetic care. This report is novel owing to the rare coexistence of a giant anaplastic oligodendroglioma with an ongoing pregnancy requiring urgent dual surgical interventions. A 27-year-old, right-handed, Middle Eastern Saudi woman at 35 weeks of gestation presented with neurological symptoms, including partial loss of consciousness, left-sided ptosis, and severe headaches. Imaging revealed a large left temporoparietal mass with significant midline shift, diagnosed as an anaplastic oligodendroglioma. She underwent an emergency cesarean section and craniotomy under general anesthesia. Postoperative recovery was uneventful for both the mother and the newborn. This case highlights the critical importance of multidisciplinary coordination, individualized anesthetic planning, and timely surgical decision-making in managing complex neurosurgical cases during pregnancy. The combined obstetric-neurosurgical approach contributed to a favorable maternal and neonatal outcome.

#2

Hematological Malignancies With Multiple Primary Cancers: A Rare Case Presentation.

Case reports in hematology2026

Two or more primary cancers that arise in two different patients are referred to as multiple primary cancers. We record those cases because optimal therapy requires interdisciplinary cooperation. A 53-year-old male presented with intermittent hematuria for one year, fever, burning micturition, appetite loss, and a 3 kg weight loss over 2 months. His CBC showed 81% atypical cells, and bone marrow aspiration and flow cytometry indicated Precursor B-ALL. He started on the BFM-2002-protocol but had persistent hematuria. The USG of the whole abdomen revealed a urinary bladder mass. TURBT and histopathology confirmed low-grade, noninvasive papillary urothelial neoplasm. Thus, he was diagnosed with Precursor B-ALL and Low-Grade Papillary Urothelial Neoplasm Noninvasive. A 53-year-old male with a history of anaplastic oligodendroglioma (diagnosed in 2022) presented to the emergency with altered sensorium, headache, and convulsions. He had received radiotherapy and chemotherapy for the past year. In December 2023, he experienced convulsions again due to a recurrence of the oligodendroglioma. His CBC showed an increasing total leukocyte count, reaching 100,000 over five months. Bone marrow and molecular studies indicated a myeloproliferative neoplasm, specifically chronic myeloid neoplasm (CMN) in the chronic phase, with BCR-ABL1 p210 positive. He was diagnosed with recurrent anaplastic oligodendroglioma (WHO Grade 3) and CMN in the chronic phase. An increased prevalence of second primary malignancy is anticipated due to the rising cancer burden and the careful screening of index initial malignancy throughout therapy. Determining the best course of action requires careful staging of the cancer and discussion by a multidisciplinary team.

#3

Investigation of mismatch repair protein expression in glioma.

Annals of diagnostic pathology2026 Feb

Mismatch repair (MMR) proteins are essential for maintaining genomic stability, and their dysfunction contributes to tumorigenesis in several malignancies. However, their role in glioma remains insufficiently defined. This study evaluated MMR protein expression in Tunisian glioma patients and examined its clinicopathological and prognostic significance. Ninety-five glioma samples were retrospectively analyzed. MMR protein expression was assessed by immunohistochemistry on formalin-fixed, paraffin-embedded tissues. Survival outcomes were evaluated using Kaplan-Meier analysis with Log-Rank testing. MMR expression was retained in 65 tumors (68.4 %) and lost in 30 (31.6 %). Loss of MLH1/PMS2 was observed in 16 tumors, MSH2/MSH6 loss in 12, and complete loss of all MMR proteins in two tumors. The distribution of MMR deficiency varied by histological subtype. Among pilocytic astrocytomas, 7 cases exhibited MMR deficiency, predominantly MLH1/PMS2 (n = 5). Two astrocytomas IDH mutant showed either MLH1/PMS2 or MSH2/MSH6 loss. Altered MMR profiles were also identified in oligodendroglioma IDH-mutant, 1p/19q co-deleted (n = 3), oligoastrocytoma NOS (n = 1), and anaplastic oligodendroglioma NOS (n = 1). In glioblastoma, IDH-wildtype, 14 cases showed heterodimer loss (MLH1/PMS2 or MSH2/MSH6), and two tumors demonstrated complete loss of all MMR proteins. Survival analysis revealed a significant prognostic effect exclusively in glioblastomas IDH-wildtype, where MMR deficiency was associated with worse survival (Log-rank test, p < 0.0001). MMR deficiency is relatively frequent in gliomas and carries prognostic significance, particularly in glioblastoma IDH-wildtype. Incorporating MMR status into molecular profiling may enhance risk stratification and inform therapeutic decision-making in glioma management.

#4

Long-Term Remission of Recurrent Anaplastic Oligodendroglioma With WT-1-Specific CD8+ T-Cell Therapy: A Case Report.

Brain tumor research and treatment2025 Apr

We report a case of complete remission in anaplastic oligodendroglioma following adoptive cell therapy (ACT) with autologous Wilms tumor 1 (WT-1)-specific CD8+ T cells. A 40-year-old woman referred to our hospital for adjuvant chemotherapy after recurrent anaplastic oligodendroglioma initially presented with a left frontal tumor, diagnosed through seizure onset, and subtotal resection confirmed oligodendroglioma (WHO grade 2). Radiation therapy treated the residual tumor, achieving partial remission until recurrence 2.5 years later when malignant transformation to anaplastic oligodendroglioma (WHO grade 3) occurred following a second craniotomy. After three cycles of procarbazine, lomustine, and vincristine chemotherapy, the residual tumor stabilized for 3 years. However, follow-up MRI identified a new enhancing lesion, prompting a third craniotomy. Recurrent anaplastic oligodendroglioma was confirmed, and adjuvant proton beam therapy and temozolomide chemotherapy were initiated. Two years later, another enhancing lesion appeared on the adjacent medial frontal lobe. Following multidisciplinary review, we introduced WT-1-specific ACT. Although transient swelling was observed 1 month post-therapy, the tumor demonstrated a response within 3-9 months. Continued regression led to complete remission-confirmed via MRI at the 15-month follow-up and sustained for 4.7 years. The patient's peripheral blood monocyte profiles and immune-associated cytokine analysis indicated T-cell activation following WT-1 sensitization.

#5

Do clinical outcomes in individuals with malignant gliomas differ between sexes?

Brain &amp; spine2025

Sex-related differences in the epidemiology of malignant gliomas are acknowledged; however, information regarding their clinical characteristics and outcomes after surgery is limited. To identify sex-specific differences of all patients with high-grade glioma at our institution and assessed clinical outcomes and prognostic factors. This single-center study included those who underwent surgery for malignant gliomas between 2010 and 2020. Categorical, normally distributed, and skewed continuous variables were compared between men and women using the chi-square test, independent samples t-test, and Mann-Whitney U test, respectively. Survival was calculated using the log-rank and Kaplan-Meier methods. In total, 621 patients with WHO grade IV gliomas were identified (370 (59.58%) male). Men were significantly younger, underwent surgery faster after imaging diagnosis, and had a slightly higher surgical complications incidence than women. Women reported a worse preoperative performance status. Multivariate analysis showed that sex did not affect survival, surgical complications, nicotine or alcohol abuse, or preoperative tumor volume. Age, Karnofsky performance status, neurosurgical resection, and adjuvant radiotherapy with temozolomide showed a survival advantage. Men are diagnosed with malignant glioma at a younger age than women; however, no advantage in clinical outcomes was observed. No sex-related differences were observed.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC186 artigos no totalmostrando 198

2026

Anesthesia management in a pregnant woman with a giant temporoparietal anaplastic oligodendroglioma: a case report.

Journal of medical case reports
2026

Hematological Malignancies With Multiple Primary Cancers: A Rare Case Presentation.

Case reports in hematology
2025

Adjuvant chemoradiotherapy with procarbazine, lomustine, and vincristine (PCV) or temozolomide for 1p/19q Co-deleted anaplastic oligodendroglioma: a systematic review and network meta-analysis.

BMC cancer
2025

Designing a web-based platform for dynamic estimation of individualized conditional survival in grade 3 gliomas.

Discover oncology
2025

Combined temozolomide, immunotherapy and radiotherapy in a patient with anaplastic oligodendroglioma and multiple extracranial metastases: A rare case report.

Medicine
2026

Investigation of mismatch repair protein expression in glioma.

Annals of diagnostic pathology
2025

In silico analysis reveals distinct changes in markers of epithelial to mesenchymal transition in glioma subtypes.

Biomolecules &amp; biomedicine
2025

Shared decision-making interventions in neuro-oncology practice: a systematic review.

Journal of neuro-oncology
2025

Long-Term Remission of Recurrent Anaplastic Oligodendroglioma With WT-1-Specific CD8+ T-Cell Therapy: A Case Report.

Brain tumor research and treatment
2025

Radiation-induced osteosarcoma of the frontoparietal calvaria 6 years after oligodendroglioma treatment: illustrative case.

Journal of neurosurgery. Case lessons
2025

Integrating nutritional status and hematological biomarkers for enhanced prognosis prediction in glioma patients: A systematic review.

Clinical nutrition ESPEN
2025

Expanded Use of Vorasidenib in Non-Enhancing Recurrent CNS WHO Grade 3 Oligodendroglioma.

Biomedicines
2025

Do clinical outcomes in individuals with malignant gliomas differ between sexes?

Brain &amp; spine
2025

A case of anaplastic oligodendroglioma in a rabbit (Oryctolagus cuniculus).

The Journal of veterinary medical science
2025

Endoscopic transorbital approach for resection of mediobasal temporal lesions using an optic radiation-sparing strategy.

Journal of neurosurgery
2024

Photodynamic therapy using talaporfin sodium for non-totally resectable malignant glioma.

Photodiagnosis and photodynamic therapy
2024

Metastases and Primary Brain Tumors Affecting the Fornix of the Brain.

Cureus
2024

Construction and Validation of Nomograms for Predicting Overall Survival and Cancer-Specific Survival in Patients with Primary Anaplastic Oligodendroglioma.

World neurosurgery
2024

From molecular signatures to radiomics: tailoring neurooncological strategies through forecasting of glioma growth.

Neurosurgical focus
2024

Survival Analysis and Correlates with Molecular Epidemiology: 10-Year Retrospective Series of High-Grade Glioma in Pakistan.

Journal of cancer &amp; allied specialties
2024

Successful desensitization in a patient with recurrent anaplastic oligodendroglioma presenting with procarbazine-mediated anaphylaxis.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
2024

High Radiation Dose to the Fornix Causes Symptomatic Radiation Necrosis in Patients with Anaplastic Oligodendroglioma.

Yonsei medical journal
2023

Non-invasive diagnosis of brain gliomas by histological type using neuroradiomics in standardized regions of interest: towards digital biopsy.

Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko
2023

Evaluation of INI1 Protein Expression Through IHC Study in Pediatric High-Grade Brain Tumors in South of Iran in 2008-2021.

Iranian journal of pathology
2023

Anaplastic oligodendroglioma with nasal invasion and systemic metastasis in a dog.

The Journal of veterinary medical science
2023

Significance of perilesional T1 hyperintense areas in the differential diagnosis of primary adult-type diffuse glioma: A case report.

Radiology case reports
2023

Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting.

Journal of cancer research and therapeutics
2023

A Rare Presentation of Multifocal Anaplastic Oligodendroglioma.

Journal of microscopy and ultrastructure
2023

Anlotinib as Monotherapy or Combination Therapy for Recurrent High-Grade Glioma: A Retrospective Study.

Clinical Medicine Insights. Oncology
2023

A Prospective Study of Intensity-modulated Radiation Therapy Using a Standard Radiation Dose for High-grade Glioma.

Cancer diagnosis &amp; prognosis
2023

[68Ga] Ga-Pentixafor diffuse bilateral Adrenal & Breast uptake in a patient with High-grade Glioma: A note of caution on normal variants.

Asia Oceania journal of nuclear medicine &amp; biology
2023

T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone.

European journal of neurology
2023

Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial.

The Lancet. Child &amp; adolescent health
2023

A rare, giant, anaplastic oligodendroglioma.

Radiology case reports
2022

The feasibility of MRI texture analysis in distinguishing glioblastoma, anaplastic astrocytoma and anaplastic oligodendroglioma.

Translational cancer research
2022

A Patient With Epilepsy, Ganglioglioma, and Oligodendroglioma With Anaplastic Foci in the Same Left Frontoparietal Lesion: A Case Report.

Cureus
2022

Alterations in white matter fiber density associated with structural MRI and metabolic PET lesions following multimodal therapy in glioma patients.

Frontiers in oncology
2023

Anaplastic oligodendroglioma presenting with apoplectic intratumoral hemorrhage.

Radiology case reports
2023

Relationship between RANO-PRO Working Group standardised priority constructs and disease progression among malignant glioma patients: A retrospective cohort study.

EClinicalMedicine
2022

The Mean ApoC1 Serum Level in Postoperative Samples from Neurosurgical Patients Is Lower than in Preoperative Samples and during Chemotherapy.

Biology
2022

True anaplastic oligoastrocytoma with dual genotype: illustrative case.

Journal of neurosurgery. Case lessons
2022

Radiosurgery and Stereotactic Brain Radiotherapy with Systemic Therapy in Recurrent High-Grade Gliomas: Is It Feasible? Therapeutic Strategies in Recurrent High-Grade Gliomas.

Journal of personalized medicine
2022

Acid and Alkaline Phosphatases Specific activities and Expression as Biomarkers in Brain Tumor Grading and Correlation of Anaplastic Oligodendroglioma G-III to Meningiomas G-I among Brain Tumors and their primary culture.

Journal of chemical neuroanatomy
2022

The Multiple Rib Osteomyocutaneous Split Latissimus Dorsi Flap for Calvarial Reconstruction: Indication, Operative Technique, and Review of Literature.

The Journal of craniofacial surgery
2022

The correlation analysis of TERT promoter mutations with IDH1/2 mutations and 1p/19q detected in human gliomas.

Medicine
2022

Analysis of the Prognosis of High-Grade gliomas in the View of New Immunohistochemistry Markers and 2016 WHO Classification.

Turkish neurosurgery
2022

Characteristics of Anaplastic Oligodendrogliomas Short-Term Survivors: A POLA Network Study.

The oncologist
2022

Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies.

Neuro-oncology advances
2022

Prognostic value of O 6-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas.

Neuro-oncology advances
2022

5-Aminolevulinic acid-enhanced fluorescence-guided treatment of high-grade glioma using angled endoscopic blue light visualization: technical case series with preliminary follow-up.

Journal of neurosurgery
2022

The oligodendroglial histological features are not independently predictive of patient prognosis in lower-grade gliomas.

Brain tumor pathology
2022

Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.

The Cochrane database of systematic reviews
2022

Cranial sonolucent prosthesis: a window of opportunity for neuro-oncology (and neuro-surgery).

Journal of neuro-oncology
2022

Large tumour volume reduction of IDH-mutated anaplastic glioma involving the insular region following radiotherapy.

BMC neurology
2022

A patient with two gliomas with independent oligodendroglioma and glioblastoma biology proved by DNA-methylation profiling: a case report and review of the literature.

Brain tumor pathology
2021

Case Report: Detection of Symptomatic Treatment-Related Changes in a Patient With Anaplastic Oligodendroglioma Using FET PET.

Frontiers in oncology
2021

SSTR2 is a prognostic factor and a promising therapeutic target in glioma.

American journal of translational research
2021

Reconstruction of Complex Scalp Defects in Different Locations: Suggestions for Puzzle.

Sisli Etfal Hastanesi tip bulteni
2021

Oligodendroglioma: A Review of Management and Pathways.

Frontiers in molecular neuroscience
2021

Infrequent RAS mutation is not associated with specific histological phenotype in gliomas.

BMC cancer
2021

Radiation Therapy for Grade 3 Gliomas: Correlation of MRI Findings With Prognosis.

Cureus
2022

[89Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma.

European journal of nuclear medicine and molecular imaging
2021

[Anaplastic astrocytoma and anaplastic oligodendroglioma of the brain: current state of the problem].

Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko
2021

[Clinicopathological and molecular genetic characteristics of adult IDH wild-type diffuse gliomas].

Zhonghua bing li xue za zhi = Chinese journal of pathology
2021

High-Dose Fluorescein Reveals Unusual Confocal Endomicroscope Imaging of Low-Grade Glioma.

Frontiers in neurology
2021

Correlation between FDG-PET uptake and survival in patients with primary brain tumors.

American journal of nuclear medicine and molecular imaging
2021

Differential expression of stem cell markers in proliferating cells in glioma.

Journal of cancer research and clinical oncology
2021

Establishment and Validation of the Detection of TERT Promoter Mutations by Human Gliomas U251 Cell Lines.

BioMed research international
2021

[Dynamic11C-methionine PET/CT in differential diagnosis of brain gliomas].

Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko
2021

Molecular biomarkers and integrated pathological diagnosis in the reclassification of gliomas.

Molecular and clinical oncology
2021

A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma.

Journal of neuro-oncology
2021

Patient-specific virtual reality technology for complex neurosurgical cases: illustrative cases.

Journal of neurosurgery. Case lessons
2021

Hypermetabolism and impaired cerebrovascular reactivity beyond the standard MRI-identified tumor border indicate diffuse glioma extended tissue infiltration.

Neuro-oncology advances
2021

Gliomas - An experience based on molecular markers.

Journal of family medicine and primary care
2021

Distinct TERT promoter C228T and C250T mutations in a patient with an oligodendroglioma: A case report.

Neuropathology : official journal of the Japanese Society of Neuropathology
2020

Effects of Aerobic and Flexibility Training on Physiological and Psychosocial Function in a Patient with Anaplastic Oligodendroglioma: A Case Report.

Journal of rehabilitation medicine. Clinical communications
2021

TEMOBIC: Phase II Trial of Neoadjuvant Chemotherapy for Unresectable Anaplastic Gliomas: An ANOCEF Study.

The oncologist
2021

IDH-mutant gliomas with additional class-defining molecular events.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
2021

Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas.

Molecules (Basel, Switzerland)
2020

CyTOF Analysis Reveals a Distinct Immunosuppressive Microenvironment in IDH Mutant Anaplastic Gliomas.

Frontiers in oncology
2020

Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy.

Frontiers in oncology
2021

Prolonged benefit to pembrolizumab in anaplastic oligodendroglioma patient with mismatch repair deficiency: a case report.

Anti-cancer drugs
2020

Phase I trial of intracerebral convection-enhanced delivery of carboplatin for treatment of recurrent high-grade gliomas.

PloS one
2020

Treatment of patients with glioma during the COVID-19 pandemic: what we learned and what we take home for the future.

Neurosurgical focus
2020

Survival outcome and prognostic factors in anaplastic oligodendroglioma: a single-institution study of 95 cases.

Scientific reports
2021

Anaplastic Oligodendroglioma - Is Adjuvant Radiotherapy Mandatory following Maximal Surgical Resection?: Grade 3 Oligo Radiotherapy.

Clinical neurology and neurosurgery
2020

Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO).

Targeted oncology
2020

Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses.

Journal of neuro-oncology
2020

Multiple metastases to the bone and bone marrow from a 1p/19q-codeleted and IDH2-mutant anaplastic oligodendroglioma: a case report and literature review.

Neuro-oncology advances
2021

Sustained response to erlotinib and rapamycin in a patient with pediatric anaplastic oligodendroglioma.

Pediatric blood &amp; cancer
2020

Alpha Internexin: A Surrogate Marker for 1p/19q Codeletion and Prognostic Marker in Anaplastic (WHO grade III) Gliomas.

Neurology India
2020

Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study.

Cancers
2020

High-grade gliomas with isocitrate dehydrogenase wild-type and 1p/19q codeleted: Atypical molecular phenotype and current challenges in molecular diagnosis.

Neuropathology : official journal of the Japanese Society of Neuropathology
2020

[Spinal cord metastasis of anaplastic oligodendroglioma of the brain without recurrence of primary tumor. Ccase report and literature review].

Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko
2020

5-Aminolevulinic Acid Multispectral Imaging for the Fluorescence-Guided Resection of Brain Tumors: A Prospective Observational Study.

Frontiers in oncology
2020

Simultaneous Bilateral Femoral Neck Fracture Due to a Tonic-Clonic Seizure and High-Dose Steroid Therapy.

Arthroplasty today
2020

Role of the default mode resting-state network for cognitive functioning in malignant glioma patients following multimodal treatment.

NeuroImage. Clinical
2020

Survival, Prognostic Factors, and Volumetric Analysis of Extent of Resection for Anaplastic Gliomas.

Cancer research and treatment
2020

Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma.

Annals of clinical and translational neurology
2020

5-ALA False-Positive in Anaplastic Oligodendroglioma, IDH-mutant and 1p/19q-codeleted.

Surgical technology international
2020

A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2020

Involvement of the Olfactory Apparatus by Gliomas.

AJNR. American journal of neuroradiology
2020

Spinal leptomeningeal oligodendrogliomatosis after resection of cerebral anaplastic oligodendoglioma with 1p19q Co-deletion - A case report.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2019

Ability of Radiomics in Differentiation of Anaplastic Oligodendroglioma From Atypical Low-Grade Oligodendroglioma Using Machine-Learning Approach.

Frontiers in oncology
2019

High-grade Glioma Masquerading as a Small Cerebral Hemorrhage: A Case Report.

Yonago acta medica
2019

CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.

Neuro-oncology
2019

[Repetitive resection and intrasurgery radiation therapy of brain malignant gliomas: history of question and modern state of problem].

Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko
2019

Radiomics-Based Machine Learning Technology Enables Better Differentiation Between Glioblastoma and Anaplastic Oligodendroglioma.

Frontiers in oncology
2019

Experience Profiling of Fluorescence-Guided Surgery I: Gliomas.

Brain tumor research and treatment
2019

The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade III Cerebral Gliomas in Adults: Version 2019.01.

Brain tumor research and treatment
2020

Ki-67 and MCM6 labeling indices are correlated with overall survival in anaplastic oligodendroglioma, IDH1-mutant and 1p/19q-codeleted: a multicenter study from the French POLA network.

Brain pathology (Zurich, Switzerland)
2019

Repeat Resection and Intraoperative Radiotherapy for Malignant Gliomas of the Brain: A History and Review of Current Techniques.

World neurosurgery
2019

Common Molecular Alterations in Canine Oligodendroglioma and Human Malignant Gliomas and Potential Novel Therapeutic Targets.

Frontiers in oncology
2019

Extent of resection and survival for oligodendroglioma: a U.S. population-based study.

Journal of neuro-oncology
2019

Neuro-Oncology Clinical Debate: PCV or temozolomide in combination with radiation for newly diagnosed high-grade oligodendroglioma.

Neuro-oncology practice
2020

A novel PTPRZ1-ETV1 fusion in gliomas.

Brain pathology (Zurich, Switzerland)
2019

Reclassification of Mongolian Diffuse Gliomas According to the Revised 2016 World Health Organization Central Nervous System Tumor Classification.

Journal of pathology and translational medicine
2019

[IDH、TERT and 1p/19q predicting clinical outcomes in patients with anaplastic oligodendroglioma].

Zhonghua yi xue za zhi
2019

Anaplastic Oligodendroglioma with Transdural Extension.

World neurosurgery
2019

Bone metastases from a 1p/19q codeleted and IDH1-mutant anaplastic oligodendroglioma: a case report.

Journal of medical case reports
2019

Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control.

Seizure
2019

Scalp Metastasis of Anaplastic Oligodendroglioma.

World neurosurgery
2020

Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
2019

Incidence trends of adult malignant brain tumors in Finland, 1990-2016.

Acta oncologica (Stockholm, Sweden)
2019

Prognostic Value of O-(2-[18F]Fluoroethyl)-L-Tyrosine PET/CT in Newly Diagnosed WHO 2016 Grade II and III Glioma.

Molecular imaging and biology
2019

PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research
2019

Glioma Simultaneously Present with Adjacent Meningioma: Case Report and Literature Review.

Asian journal of neurosurgery
2019

c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas.

World neurosurgery
2019

Widely metastatic IDH1-mutant glioblastoma with oligodendroglial features and atypical molecular findings: a case report and review of current challenges in molecular diagnostics.

Diagnostic pathology
2019

Prognostic factors associated with survival in patients with anaplastic oligodendroglioma.

PloS one
2019

Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management.

Journal of medical imaging and radiation oncology
2019

Determination of genetic aberrations and novel transcripts involved in the pathogenesis of oligodendroglioma using array comparative genomic hybridization and next generation sequencing.

Oncology letters
2019

Anaplastic Oligodendroglioma Found as an Incidental Photopenic Lesion on 18F-FP-CIT PET/CT Image.

Clinical nuclear medicine
2019

Sequencing of Chemotherapy and Radiotherapy for Newly Diagnosed Anaplastic Oligodendroglioma and Oligoastrocytoma.

American journal of clinical oncology
2019

Anaplastic oligodendroglioma metastasizing to the bone marrow: a unique case report and literature review.

The International journal of neuroscience
2018

Tumour-to-Tumour Metastasis Phenomenon: Metastatic Prostatic Adenocarcinoma within an Anaplastic Oligodendroglioma in the Brain of a Dog.

Journal of comparative pathology
2019

Tumour volume reduction following PET guided intensity modulated radiation therapy and temozolomide in IDH mutated anaplastic glioma.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2018

Anaplastic Glioma: Treatment Approaches in the Era of Molecular Diagnostics.

Current treatment options in oncology
2019

Navigated Transcranial Magnetic Stimulation in Patient with Cranioplasty in Situ: Safe and Accurate Procedure.

World neurosurgery
2018

Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted.

Revista de neurologia
2018

Multiple Extraneural Metastases of Anaplastic Oligodendroglioma.

Asian journal of neurosurgery
2018

Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome.

Acta neuropathologica communications
2018

Anaplastic oligodendroglioma with leptomeningeal dissemination in a french bulldog.

The Journal of veterinary medical science
2018

[Li-Fraumeni syndrome in a patient with multiple anaplastic oligodendrogliomas of the brain (a case report and literature review)].

Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko
2018

Grade II and III Oligodendroglioma and Astrocytoma.

Neurologic clinics
2018

Fluorescence-guidance in non-Gadolinium enhancing, but FET-PET positive gliomas.

Clinical neurology and neurosurgery
2018

Machine Learning for Better Prognostic Stratification and Driver Gene Identification Using Somatic Copy Number Variations in Anaplastic Oligodendroglioma.

The oncologist
2018

Efficacy of Gamma Knife Radiosurgery for Recurrent High-Grade Gliomas with Limited Tumor Volume.

Journal of Korean Neurosurgical Society
2019

Clinical and Molecular Recursive Partitioning Analysis of High-grade Glioma Treated With IMRT.

American journal of clinical oncology
2018

Expression of Oligodendrocyte Precursor Cell Markers in Canine Oligodendrogliomas.

Veterinary pathology
2018

Cytomegalovirus Hemorrhagic Cystitis in a Malignant Glioma Patient Treated with Temozolomide.

Internal medicine (Tokyo, Japan)
2018

Staphylococcus epidermidis meningitis in the absence of a neurosurgical device secondary to catheter-related bloodstream infection: a case report and review of the literature.

Journal of medical case reports
2018

Reclassification of 400 consecutive glioma cases based on the revised 2016WHO classification.

Brain tumor pathology
2018

Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.

Brain tumor pathology
2018

NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.

Journal of neuro-oncology
2018

Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab.

CNS oncology
2018

Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas.

CNS oncology
2018

Recurrence patterns after maximal surgical resection and postoperative radiotherapy in anaplastic gliomas according to the new 2016 WHO classification.

Scientific reports
2018

A case of radiation-induced osteosarcoma of the skull presenting as a cutaneous epidermotropic tumor with a short latent period.

Journal of cutaneous pathology
2017

Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas.

Journal for immunotherapy of cancer
2017

Rechallenge temozolomide in glioma: A case series from India.

Indian journal of cancer
2017

A Case of Anaplastic Oligodendroglioma With Extensive Extraneural Metastases Imaged With FDG PET.

Clinical nuclear medicine
2018

SEOM clinical guidelines for anaplastic gliomas (2017).

Clinical &amp; translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
2017

[Application of ATRX in diagnosis and prognostic evaluation of glioma].

Zhonghua bing li xue za zhi = Chinese journal of pathology
2017

Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma.

Nature
2018

Reclassification of Mixed Oligoastrocytic Tumors Using a Genetically Integrated Diagnostic Approach.

Journal of pathology and translational medicine
2018

Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI.

Journal of neurosurgery
2017

Regression of Recurrent High-Grade Glioma with Temozolomide, Dexamethasone, and Levetiracetam: Case Report and Review of the Literature.

World neurosurgery
2017

Multimodal 18F-Fluciclovine PET/MRI and Ultrasound-Guided Neurosurgery of an Anaplastic Oligodendroglioma.

World neurosurgery
2017

A Case of Congenital Brainstem Oligodendroglioma: Pathology Findings and Review of the Literature.

Case reports in neurological medicine
2017

Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature.

Pediatric blood &amp; cancer
2017

Diffuse Infiltrating Oligodendroglioma and Astrocytoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2017

Cerebrospinal fluid dissemination of high-grade gliomas following boron neutron capture therapy occurs more frequently in the small cell subtype of IDH1R132H mutation-negative glioblastoma.

Journal of neuro-oncology
2017

Immunoglobulin D Multiple Myeloma Presenting as Spontaneous Fracture.

Case reports in oncology
2017

Some characteristics of gliomas managed at a Neurosurgery centre in Nigeria.

The Nigerian postgraduate medical journal
2017

Treatment Outcomes in 1p19q Co-deleted/Partially Deleted Gliomas.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
2016

A case series of salvage CCNU in high-grade glioma who have previously received temozolomide from a tertiary care institute in Mumbai.

Indian journal of cancer
2017

Value of Minimum Apparent Diffusion Coefficient on Magnetic Resonance Imaging as a Biomarker for Predicting Progression of Disease Following Surgery and Radiotherapy in Glial Tumors from a Tertiary Care Center in Northern India.

Journal of neurosciences in rural practice
2017

Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.

Neuro-oncology
2017

Improving contrast enhancement in magnetic resonance imaging using 5-aminolevulinic acid-induced protoporphyrin IX for high-grade gliomas.

Oncology letters
2017

Genetic landscape of extreme responders with anaplastic oligodendroglioma.

Oncotarget
2017

Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors.

Molecular medicine (Cambridge, Mass.)
2017

Diffuse leptomeningeal glioneuronal tumor (DLGNT) mimicking Whipple's disease: a case report and literature review.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2017

Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern.

International journal of molecular sciences
2018

Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide.

American journal of clinical oncology
2017

Bevacizumab in high-grade glioma patients following intraparenchymal hemorrhage.

Neuro-oncology practice
2017

Feline glioma: a retrospective study and review of the literature.

Journal of feline medicine and surgery
2017

Efficacy of bevacizumab therapy for unresectable malignant glioma: A retrospective analysis.

Molecular and clinical oncology
2017

Histological spectrum of oligodendroglial tumors: Only a subset shows 1p/19q codeletion.

Neurology India
2017

Effects of the functional HOTAIR rs920778 and rs12826786 genetic variants in glioma susceptibility and patient prognosis.

Journal of neuro-oncology
2017

Racial disparities in anaplastic oligodendroglioma: An analysis on 1643 patients.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2017

Molecular characterization reveals NF1 deletions and FGFR1-activating mutations in a pediatric spinal oligodendroglioma.

Pediatric blood &amp; cancer
2017

Tumor cells with neuronal intermediate progenitor features define a subgroup of 1p/19q co-deleted anaplastic gliomas.

Brain pathology (Zurich, Switzerland)
2016

Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients.

Journal of neuro-oncology
2017

Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group.

Neurologia medico-chirurgica
2016

Expression profiling of RE1-silencing transcription factor (REST), REST corepressor 1 (RCOR1), and Synapsin 1 (SYN1) genes in human gliomas.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology
2017

The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients.

Turkish neurosurgery
2016

Caring for Patients with Newly Diagnosed High-Grade Gliomas.

Seminars in neurology

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Oligodendroglioma anaplásico.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Oligodendroglioma anaplásico

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ainda não achamos doenças com sintomas parecidos o suficiente.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Anesthesia management in a pregnant woman with a giant temporoparietal anaplastic oligodendroglioma: a case report.
    Journal of medical case reports· 2026· PMID 41851906mais citado
  2. Hematological Malignancies With Multiple Primary Cancers: A Rare Case Presentation.
    Case reports in hematology· 2026· PMID 41624688mais citado
  3. Investigation of mismatch repair protein expression in glioma.
    Annals of diagnostic pathology· 2026· PMID 41130168mais citado
  4. Long-Term Remission of Recurrent Anaplastic Oligodendroglioma With WT-1-Specific CD8+ T-Cell Therapy: A Case Report.
    Brain tumor research and treatment· 2025· PMID 40347129mais citado
  5. Do clinical outcomes in individuals with malignant gliomas differ between sexes?
    Brain &amp; spine· 2025· PMID 39834719mais citado
  6. Adjuvant chemoradiotherapy with procarbazine, lomustine, and vincristine (PCV) or temozolomide for 1p/19q Co-deleted anaplastic oligodendroglioma: a systematic review and network meta-analysis.
    BMC Cancer· 2025· PMID 41254593recente
  7. Designing a web-based platform for dynamic estimation of individualized conditional survival in grade 3 gliomas.
    Discov Oncol· 2025· PMID 41249681recente
  8. Combined temozolomide, immunotherapy and radiotherapy in a patient with anaplastic oligodendroglioma and multiple extracranial metastases: A rare case report.
    Medicine (Baltimore)· 2025· PMID 41137316recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:251630(Orphanet)
  2. MONDO:0016696(MONDO)
  3. GARD:9472(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Artigo Wikipedia(Wikipedia)
  7. Q84955701(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Oligodendroglioma anaplásico
Compêndio · Raras BR

Oligodendroglioma anaplásico

ORPHA:251630 · MONDO:0016696
Prevalência
<1 / 1 000 000
Herança
Not applicable
CID-10
C71.9 · Neoplasia maligna do encéfalo, não especificado
CID-11
Ensaios
12 ativos
Início
Adult
Prevalência
0.09 (Europe)
MedGen
UMLS
C0334590
Repurposing
1 candidato
5-aminolevulinic-acidoxidizing agent
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades